A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population?

IF 5.3 1区 医学 Q1 PSYCHIATRY Addiction Pub Date : 2025-02-10 DOI:10.1111/add.70005
Basak Tas, Nicola J. Kalk, Edward Chesney, Rob van der Waal, Alastair Boyd, James Bell, Mike Kelleher, John Moxham, Will Lawn, Caroline J. Jolley, John Strang
{"title":"A heroin overdose laboratory model: How do escalating doses of diamorphine alter respiratory function in a diamorphine-treated population?","authors":"Basak Tas,&nbsp;Nicola J. Kalk,&nbsp;Edward Chesney,&nbsp;Rob van der Waal,&nbsp;Alastair Boyd,&nbsp;James Bell,&nbsp;Mike Kelleher,&nbsp;John Moxham,&nbsp;Will Lawn,&nbsp;Caroline J. Jolley,&nbsp;John Strang","doi":"10.1111/add.70005","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background &amp; Aim</h3>\n \n <p>Globally, more than 100 000 people die annually from opioid overdose. Although strongly implicated in heroin overdose deaths, acute opioid-induced respiratory depression is poorly understood, and few laboratory studies have been completed in human subjects. It is an area of undone science. Using a human laboratory overdose model, our research question was: what is the strength of the association between increasing dose of diamorphine and degree of respiratory depression in people prescribed injectable diamorphine for heroin use disorder?</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>Single-blind, Phase IV, non-randomised, dose-escalation clinical trial.</p>\n </section>\n \n <section>\n \n <h3> Setting</h3>\n \n <p>King's Clinical Research Facility, London, UK.</p>\n </section>\n \n <section>\n \n <h3> Participants</h3>\n \n <p>Four participants prescribed injectable diamorphine as treatment for heroin use disorder [all male, median (range) age 63 (59–72)].</p>\n </section>\n \n <section>\n \n <h3> Interventions</h3>\n \n <p>The following dosing schedule was implemented (as a % of participant's usual prescribed diamorphine dose): visit 1–100%; visit 2–110%; visit 3–120%; visit 4–100%. Usual dose: 97.5 mg (30 mg–200 mg).</p>\n </section>\n \n <section>\n \n <h3> Measurements</h3>\n \n <p>Physiological measures included: pulse oximetry (SpO<sub>2</sub>%), end-tidal CO<sub>2</sub> (ETCO<sub>2</sub>%), transcutaneous CO<sub>2</sub>, respiratory rate and parasternal electromyography to measure neural respiratory drive index (NRDI). Recordings were made continuously from 3 mins pre-dose to 60 mins post-dose.</p>\n </section>\n \n <section>\n \n <h3> Findings</h3>\n \n <p>Respiratory measures from baseline to post-dose across all dose sessions had ranges of: 89.7%–99.5% SpO<sub>2</sub>%; 4.8%–7.7% ETCO<sub>2</sub>%; 5.2–13.4 breaths/minute respiratory rate; 51.2 min<sup>−1</sup>–165.9 min<sup>−1</sup> NRDI across all participants. All diamorphine doses caused some reduction in respiratory function. There was no clear difference between diamorphine dose and the degree of respiratory depression, based on descriptive analyses.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>A dose-escalation clinical trial of people prescribed injectable diamorphine for heroin addiction found that the degree of respiratory depression caused by diamorphine does not appear to be dose dependent; however, the changes seen at diamorphine doses to which participants were accustomed suggest that participants had only partial tolerance to the respiratory depressant effect of diamorphine.</p>\n </section>\n </div>","PeriodicalId":109,"journal":{"name":"Addiction","volume":"120 6","pages":"1253-1259"},"PeriodicalIF":5.3000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.70005","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Addiction","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/add.70005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background & Aim

Globally, more than 100 000 people die annually from opioid overdose. Although strongly implicated in heroin overdose deaths, acute opioid-induced respiratory depression is poorly understood, and few laboratory studies have been completed in human subjects. It is an area of undone science. Using a human laboratory overdose model, our research question was: what is the strength of the association between increasing dose of diamorphine and degree of respiratory depression in people prescribed injectable diamorphine for heroin use disorder?

Design

Single-blind, Phase IV, non-randomised, dose-escalation clinical trial.

Setting

King's Clinical Research Facility, London, UK.

Participants

Four participants prescribed injectable diamorphine as treatment for heroin use disorder [all male, median (range) age 63 (59–72)].

Interventions

The following dosing schedule was implemented (as a % of participant's usual prescribed diamorphine dose): visit 1–100%; visit 2–110%; visit 3–120%; visit 4–100%. Usual dose: 97.5 mg (30 mg–200 mg).

Measurements

Physiological measures included: pulse oximetry (SpO2%), end-tidal CO2 (ETCO2%), transcutaneous CO2, respiratory rate and parasternal electromyography to measure neural respiratory drive index (NRDI). Recordings were made continuously from 3 mins pre-dose to 60 mins post-dose.

Findings

Respiratory measures from baseline to post-dose across all dose sessions had ranges of: 89.7%–99.5% SpO2%; 4.8%–7.7% ETCO2%; 5.2–13.4 breaths/minute respiratory rate; 51.2 min−1–165.9 min−1 NRDI across all participants. All diamorphine doses caused some reduction in respiratory function. There was no clear difference between diamorphine dose and the degree of respiratory depression, based on descriptive analyses.

Conclusions

A dose-escalation clinical trial of people prescribed injectable diamorphine for heroin addiction found that the degree of respiratory depression caused by diamorphine does not appear to be dose dependent; however, the changes seen at diamorphine doses to which participants were accustomed suggest that participants had only partial tolerance to the respiratory depressant effect of diamorphine.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
海洛因过量的实验室模型:不断增加的吗啡剂量如何改变吗啡治疗人群的呼吸功能?
背景与目的:在全球范围内,每年有超过10万人死于阿片类药物过量。尽管与海洛因过量死亡密切相关,但人们对阿片类药物引起的急性呼吸抑制知之甚少,并且在人类受试者中完成的实验室研究很少。这是一个未完成的科学领域。使用人类实验室过量模型,我们的研究问题是:在海洛因使用障碍的患者中,注射diamorphine增加剂量和呼吸抑制程度之间的关联强度是什么?设计:单盲、IV期、非随机、剂量递增临床试验。地点:英国伦敦国王临床研究中心。参与者:4名参与者处方注射海洛因吗啡作为海洛因使用障碍的治疗[所有男性,年龄中位数(范围)为63(59-72)]。干预措施:实施以下给药计划(占参与者通常处方diamorphine剂量的%):访问1-100%;访问2 - 110%;访问3 - 120%;访问4 - 100%。常用剂量:97.5毫克(30毫克-200毫克)。生理测量包括:脉搏血氧仪(SpO2%)、潮末CO2 (ETCO2%)、经皮CO2、呼吸频率和胸骨旁肌电图测量神经呼吸驱动指数(NRDI)。从给药前3分钟至给药后60分钟连续记录。结果:在所有剂量期间,从基线到给药后的呼吸测量值范围为:89.7%-99.5% SpO2%;ETCO2% 4.8% - -7.7%;5.2 ~ 13.4次/分呼吸速率;51.2 min-1-165.9 min-1 NRDI。所有的吗啡剂量都会引起呼吸功能的一定程度的下降。描述性分析显示,吗啡剂量与呼吸抑制程度无明显差异。结论:一项剂量递增的临床试验发现,海洛因成瘾者服用注射吗啡引起的呼吸抑制程度不存在剂量依赖性;然而,在参与者习惯的吗啡剂量下观察到的变化表明,参与者对吗啡的呼吸抑制作用只有部分耐受性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Addiction
Addiction 医学-精神病学
CiteScore
10.80
自引率
6.70%
发文量
319
审稿时长
3 months
期刊介绍: Addiction publishes peer-reviewed research reports on pharmacological and behavioural addictions, bringing together research conducted within many different disciplines. Its goal is to serve international and interdisciplinary scientific and clinical communication, to strengthen links between science and policy, and to stimulate and enhance the quality of debate. We seek submissions that are not only technically competent but are also original and contain information or ideas of fresh interest to our international readership. We seek to serve low- and middle-income (LAMI) countries as well as more economically developed countries. Addiction’s scope spans human experimental, epidemiological, social science, historical, clinical and policy research relating to addiction, primarily but not exclusively in the areas of psychoactive substance use and/or gambling. In addition to original research, the journal features editorials, commentaries, reviews, letters, and book reviews.
期刊最新文献
Contingency management interventions for substance use and addictive behaviours: Review of the United Kingdom evidence base. Social cognition in Korsakoff's syndrome: A meta-analysis. Heated tobacco product use and tobacco abstinence: A prospective cohort study. Examining changes in the prevalence of cost-motivated alcohol reduction attempts in the context of a cost-of-living crisis and alcohol duty reforms: A population survey of risky drinkers in Great Britain, 2021-2024. Motivational smoking cessation counselling and community-based follow-up after hospitalisation for vascular disease: A randomised controlled trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1